HighTide Therapeutics Inc.
https://www.hightidetx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From HighTide Therapeutics Inc.
Intercept Ends NASH Development, But Other Firms’ FXR Agonist Programs Ongoing
While Intercept is calling it quits in NASH with its FXR agonist obeticholic acid following a second complete response letter, other companies are staying the course with Phase II molecules in the class.
Latest Big Rounds Herald A China Biotech Funding Spring?
Around the turn of the year, four Chinese biotechs including Kelun Biotech and BioRay ramped up funding with deals worth more than $100m, at a time when overall investment sentiment in the sector remains gloomy.
Finance Watch: VC Round Extensions Attractive While Stock Market Wobbles
Private Company Edition: While Coya Therapeutics raised $15.25m in the final initial public offering in the US last year, Apnimed stayed private raising $80m in a series C extension and Metagenomi extended its series B by $100m to total $275m.
Asia Executives To Watch: Alcon Japan New President, AZ International EVP
Autumn has brought a flurry of personnel changes with Kyowa FujiFilm getting a new president and AZ a new executive vice president for the international region. Fosun and the medtech firm, Median Technologies, have also seen personnel movement.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- HighTide Biopharma Pty Ltd
- Shenzhen HighTide Biopharmaceutical Ltd
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice